Navigation Links
Omeros Reports Initiation of Phase 2 Clinical Trial with OMS824
Date:9/19/2013

SEATTLE, Sept. 19, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced initiation of enrollment in a Phase 2 clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor. The trial will evaluate the compound's tolerability, safety, pharmacokinetics, potential interactions with concomitant antipsychotic medications, and a battery of cognitive tests in patients with stable schizophrenia.

The Phase 1 clinical program in healthy subjects established dosing regimens that were well tolerated and associated with high levels of PDE10 target engagement in the brain, supporting advancement of OMS824 into patient-directed trials. In this Phase 2 clinical trial, OMS824 will be administered at various dose levels for two weeks to patients whose antipsychotic medications have been temporarily discontinued or who continue their usual antipsychotic regimen in order to assess the effects of OMS824 as monotherapy and in combination with antipsychotic medications. A variety of cognitive tests will be assessed, although the relatively small size of this trial will limit the ability to detect treatment effects, if present.  The safety and any efficacy findings in this trial are planned for use in determining appropriate dosing regimens and selecting endpoints for subsequent Phase 2 and Phase 3 clinical trials in schizophrenia. Those trials are expected to evaluate OMS824 in schizophrenic patients who are psychiatrically stable with cognitive impairment, in patients with acute exacerbation of symptoms, and/or in patients with inadequate response to antipsychotic medications.

"We are excited to begin assessing OMS824 in patients suffering with schizophrenia," stated Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. "This Phase 2 trial will provide us with important information on our compound's safety and, potentially, efficacy for additional Phase 2 trials in schizophrenia and Huntington's disease. We look forward to completing the current trial later this year."  

About Omeros' PDE10 Program

PDE10 is an enzyme that is expressed in areas of the brain linked to diseases that affect cognition and psychomotor functions, including Huntington's disease and schizophrenia. Huntington's disease is a hereditary neurodegenerative disorder that leads to movement, cognition, and behavioral abnormalities and premature death. Schizophrenia is a group of severe brain disorders characterized by an abnormal interpretation of reality, which can manifest as delusions, hallucinations, and/or disordered thinking and behavior. Cognitive dysfunction is responsible for substantial disability in both of these diseases and is not meaningfully improved by current medications. Omeros' proprietary compound OMS824 inhibits PDE10 and is being developed for the treatment of cognitive disorders. In addition to potential benefits on cognition, OMS824 could also improve the motor and psychiatric abnormalities in Huntington's disease as well as the positive (e.g., hallucinations) and negative (e.g., flat affect) symptoms of schizophrenia.

About Omeros Corporation

Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. The Company's most clinically advanced product candidates, OMS302 for lens replacement surgery and OMS103HP for arthroscopy, are derived from its proprietary PharmacoSurgery® platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has six clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the pharmaceutical industry. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, coagulopathies and central nervous system disorders.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are subject to the "safe harbor" created by those sections for such statements. These statements include, but are not limited to, Omeros' expectations regarding subsequent Phase 2 and 3 clinical trials; the timing of completion of the current trial; the potential therapeutic benefits of OMS824; the potential qualities of OMS824; and that it may have capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the pharmaceutical industry. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Omeros' actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors described under the heading "Risk Factors" in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 9, 2013. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the Company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future.


'/>"/>
SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Omeros Reports Additional Positive Results from OMS824 Program
2. Omeros Submits OMS302 Marketing Authorization Application to European Medicines Agency
3. Omeros to Present at the Stifel Healthcare Conference 2013
4. Michael A. Jacobsen Joining Omeros as Vice President, Finance and Chief Accounting Officer
5. Omeros Corporation Reports Second Quarter 2013 Financial Results
6. Omeros to Present at the Wedbush 2013 Life Sciences Management Access Conference
7. Omeros Submits New Drug Application to U.S. FDA for OMS302
8. Omeros Reports Positive Results from OMS824 Positron Emission Tomography Clinical Trial
9. Omeros Files Clinical Trial Application for Lead Antibody in MASP-2 Program
10. Omeros Corporation Reports First Quarter 2013 Financial Results
11. Omeros Announces $16.2 Million Registered Direct Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... 2016  The ALS Association, in partnership with ALS Finding ... generate a biomarker to track TDP43 aggregation. The successful team(s) ... $1 million investment. --> ... nerve cells in the brain and the spinal cord. Eventually, ... muscle movement, which often leads to total paralysis and death ...
(Date:2/10/2016)... , Feb. 10, 2016  LexisNexis® Risk ... technology, today announced the launch of LexisNexis ... solution that helps improve and optimize the quality ... of performance using severity-adjusted scores. By measuring provider ... critical solution to deliver better outcomes, improve the ...
(Date:2/10/2016)... CORAL SPRINGS, Florida , February 10, 2016 ... Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS ) and Celldex Therapeutics, ... Medivation, Inc. (NASDAQ: MDVN ), Adamas Pharmaceuticals, Inc. (NASDAQ: ... ). --> Today,s latest Orphan Drug Designations become ... granted by the FDA to novel drugs and biologics which ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... ... as the World Molecular Imaging Congress (WMIC), will be held in New York ... meeting is “Imaging Biology…Improving Therapy.” The congress will highlight and emphasize how imaging ...
(Date:2/10/2016)... Rancho Mirage, California (PRWEB) , ... February 10, ... ... Care Dental are working together to expand dental health services to the developmentally ... have moved We Care Dental’s operations to a new facility at 71-949 Highway ...
(Date:2/10/2016)... ... February 10, 2016 , ... Compliancy ... to associations of medical professionals throughout the country. The Guard was specifically designed ... policies and procedures, employee training, regulatory updates, and compliance coaching. , In addition ...
(Date:2/10/2016)... Thornton, CO (PRWEB) , ... February 10, 2016 , ... ... to announce the practice is now accepting new dental patients and families in the ... expect exceptional dental care services from cleanings to cosmetic dentistry, and all in the ...
(Date:2/10/2016)... ... ... AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral ... December 31, 2015 on Monday, February 29, 2016 after the market closes. , The ... release at 4:30 PM ET. Investors interested in participating by phone are invited to ...
Breaking Medicine News(10 mins):